Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Current Deferred Revenue of -$759524.9 for Q4 2025, down 209.07% sequentially from $696371.8 in Q2 2025, and up 59.69% YoY from -$475626.4 in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Current Deferred Revenue for 10 years, with the latest figure at -$759524.9 in Q4 2025.
- Quarterly Current Deferred Revenue rose 59.69% year-over-year to -$759524.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$759524.9 (up 59.69% YoY) and the FY2025 annual result came in at -$752869.4, up 60.04% from the prior year.
- Current Deferred Revenue retreated to -$759524.9 in Q4 2025 per BDRX's latest filing, from $696371.8 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.4 million in Q4 2021 and troughed at -$1.9 million in Q4 2024.
- A 4-year average of -$34199.7 and a median of $174146.2 in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue soared 1652.32% in 2021, then slumped 116.58% in 2022.
- Over 4 years, Current Deferred Revenue stood at $1.4 million in 2021, then slumped by 116.58% to -$231066.9 in 2022, then sank by 715.43% to -$1.9 million in 2024, then soared by 59.69% to -$759524.9 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered -$759524.9, $696371.8, and -$1.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -759,524.90 |
| Jun 30, 2025 | 696,371.85 |
| Dec 31, 2024 | -1.88 Mn |
| Jun 30, 2024 | 579,359.32 |
| Dec 31, 2022 | -231,066.88 |
| Dec 31, 2021 | 1.39 Mn |
| Dec 31, 2020 | -89,790.67 |
| Jun 30, 2019 | 3.30 Mn |
| Dec 31, 2018 | 1.70 Mn |
| Dec 31, 2015 | 2.09 Mn |
| Dec 31, 2014 | 248,751.29 |
| Dec 31, 2013 | 238,003.77 |